Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Grants Emergency Use Authorization To Variety Of OTC COVID-19 Tests

Executive Summary

The US agency has granted emergency use authorization to consumer COVID-19 testing products from Quidel, Abbott and BD.

You may also be interested in...



Abbott’s Q2 Medical Device And Diagnostic Sales Surpass 2019 Levels

Abbott expects the ongoing recovery of medical procedure volumes to continue even as new virus variants are causing COVID-19 cases to increase in some geographies.

NIH, CDC Distributing OTC COVID-19 Tests In US Study On Reducing Community Transmission

NIH pays for 2 million Quidel QuickVue tests in a program it is conducting with the CDC to determine whether frequent self-administered testing helps reduce community transmission of SARS-CoV-2.

Abbott Receives US Authorization For First 'Virtually Guided' At-Home Rapid Test

Abbott plans to deliver 30 million BinaxNOW prescription, at-home rapid tests in the first quarter of 2021; 90 million more in the second quarter.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT143730

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel